TY  - JOUR
AU  - Rosania, Rosa
AU  - Von Arnim, Ulrike
AU  - Link, Alexander
AU  - Rajilić-Stojanović, Mirjana
AU  - Franck, Caspar
AU  - Canbay, Ali
AU  - Malfertheiner, Peter
AU  - Venerito, Marino
PY  - 2018
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/4013
AB  - Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.
PB  - Medical Univ Press, Cluj-Napoca
T2  - Journal of Gastrointestinal and Liver Diseases
T1  - Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study
EP  - 125
IS  - 2
SP  - 119
VL  - 27
DO  - 10.15403/jgld.2014.1121.272.hpy
ER  - 

@article{
author = "Rosania, Rosa and Von Arnim, Ulrike and Link, Alexander and Rajilić-Stojanović, Mirjana and Franck, Caspar and Canbay, Ali and Malfertheiner, Peter and Venerito, Marino",
year = "2018",
abstract = "Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.",
publisher = "Medical Univ Press, Cluj-Napoca",
journal = "Journal of Gastrointestinal and Liver Diseases",
title = "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study",
pages = "125-119",
number = "2",
volume = "27",
doi = "10.15403/jgld.2014.1121.272.hpy"
}

Rosania, R., Von Arnim, U., Link, A., Rajilić-Stojanović, M., Franck, C., Canbay, A., Malfertheiner, P.,& Venerito, M.. (2018). Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study. in Journal of Gastrointestinal and Liver Diseases
Medical Univ Press, Cluj-Napoca., 27(2), 119-125.
https://doi.org/10.15403/jgld.2014.1121.272.hpy

Rosania R, Von Arnim U, Link A, Rajilić-Stojanović M, Franck C, Canbay A, Malfertheiner P, Venerito M. Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study. in Journal of Gastrointestinal and Liver Diseases. 2018;27(2):119-125.
doi:10.15403/jgld.2014.1121.272.hpy .

Rosania, Rosa, Von Arnim, Ulrike, Link, Alexander, Rajilić-Stojanović, Mirjana, Franck, Caspar, Canbay, Ali, Malfertheiner, Peter, Venerito, Marino, "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study" in Journal of Gastrointestinal and Liver Diseases, 27, no. 2 (2018):119-125,
https://doi.org/10.15403/jgld.2014.1121.272.hpy . .

TY  - JOUR
AU  - Cammarota, Giovanni
AU  - Ianiro, Gianluca
AU  - Tilg, Herbert
AU  - Rajilić-Stojanović, Mirjana
AU  - Kump, Patrizia
AU  - Satokari, Reetta
AU  - Sokol, Harry
AU  - Arkkila, Perttu
AU  - Pintus, Cristina
AU  - Hart, Ailsa
AU  - Segal, Jonathan
AU  - Aloi, Marina
AU  - Masucci, Luca
AU  - Molinaro, Antonio
AU  - Scaldaferri, Franco
AU  - Gasbarrini, Giovanni
AU  - Lopez-Sanroman, Antonio
AU  - Link, Alexander
AU  - De Groot, Pieter
AU  - de Vos, Willem M.
AU  - Hoegenauer, Christoph
AU  - Malfertheiner, Peter
AU  - Mattila, Eero
AU  - Milosavljević, Tomica
AU  - Nieuwdorp, Max
AU  - Sanguinetti, Maurizio
AU  - Simren, Magnus
AU  - Gasbarrini, Antonio
PY  - 2017
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/3706
AB  - Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.
PB  - Bmj Publishing Group, London
T2  - GUT
T1  - European consensus conference on faecal microbiota transplantation in clinical practice
EP  - 580
IS  - 4
SP  - 569
VL  - 66
DO  - 10.1136/gutjnl-2016-313017
ER  - 

@article{
author = "Cammarota, Giovanni and Ianiro, Gianluca and Tilg, Herbert and Rajilić-Stojanović, Mirjana and Kump, Patrizia and Satokari, Reetta and Sokol, Harry and Arkkila, Perttu and Pintus, Cristina and Hart, Ailsa and Segal, Jonathan and Aloi, Marina and Masucci, Luca and Molinaro, Antonio and Scaldaferri, Franco and Gasbarrini, Giovanni and Lopez-Sanroman, Antonio and Link, Alexander and De Groot, Pieter and de Vos, Willem M. and Hoegenauer, Christoph and Malfertheiner, Peter and Mattila, Eero and Milosavljević, Tomica and Nieuwdorp, Max and Sanguinetti, Maurizio and Simren, Magnus and Gasbarrini, Antonio",
year = "2017",
abstract = "Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.",
publisher = "Bmj Publishing Group, London",
journal = "GUT",
title = "European consensus conference on faecal microbiota transplantation in clinical practice",
pages = "580-569",
number = "4",
volume = "66",
doi = "10.1136/gutjnl-2016-313017"
}

Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., Segal, J., Aloi, M., Masucci, L., Molinaro, A., Scaldaferri, F., Gasbarrini, G., Lopez-Sanroman, A., Link, A., De Groot, P., de Vos, W. M., Hoegenauer, C., Malfertheiner, P., Mattila, E., Milosavljević, T., Nieuwdorp, M., Sanguinetti, M., Simren, M.,& Gasbarrini, A.. (2017). European consensus conference on faecal microbiota transplantation in clinical practice. in GUT
Bmj Publishing Group, London., 66(4), 569-580.
https://doi.org/10.1136/gutjnl-2016-313017

Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, De Groot P, de Vos WM, Hoegenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A. European consensus conference on faecal microbiota transplantation in clinical practice. in GUT. 2017;66(4):569-580.
doi:10.1136/gutjnl-2016-313017 .

Cammarota, Giovanni, Ianiro, Gianluca, Tilg, Herbert, Rajilić-Stojanović, Mirjana, Kump, Patrizia, Satokari, Reetta, Sokol, Harry, Arkkila, Perttu, Pintus, Cristina, Hart, Ailsa, Segal, Jonathan, Aloi, Marina, Masucci, Luca, Molinaro, Antonio, Scaldaferri, Franco, Gasbarrini, Giovanni, Lopez-Sanroman, Antonio, Link, Alexander, De Groot, Pieter, de Vos, Willem M., Hoegenauer, Christoph, Malfertheiner, Peter, Mattila, Eero, Milosavljević, Tomica, Nieuwdorp, Max, Sanguinetti, Maurizio, Simren, Magnus, Gasbarrini, Antonio, "European consensus conference on faecal microbiota transplantation in clinical practice" in GUT, 66, no. 4 (2017):569-580,
https://doi.org/10.1136/gutjnl-2016-313017 . .